Ensysce Biosciences, Inc.
ENSC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001716947
In the last 90 days, Ensysce Biosciences, Inc. insiders filed 1 open-market purchase and 0 sales; 18 institutions reported holding it in 13F filings for Q2 2026, worth $261.1K in total; no superinvestor holds it.
Q3 2022 vs. Q2 2022
How the institutions holding Ensysce Biosciences, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 21 | 20 | −1 |
| Shares | 3.92M | 3.78M | −140.3K (−3.6%) |
| Value | $3.41M | $810.7K | −$2.59M (−76.2%) |
New holders (5)
Institutions that held Ensysce Biosciences, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cerity Partners LLC | 150,000 | $32.0K | 0.00% |
| Northern Trust Corp | 51,089 | $11.0K | 0.00% |
| Virtu Financial LLC | 41,789 | $9.00K | 0.00% |
| Jane Street Group, LLC | 20,431 | $4.00K | 0.00% |
| Moneta Group Investment Advisors LLC | 5,116 | – | – |
Sold out (6)
Institutions that held Ensysce Biosciences, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.
| Institution | Shares, Q2 2022 | Value, Q2 2022 |
|---|---|---|
| Renaissance Technologies LLC | 356,325 | $309.0K |
| Anson Funds Management LP | 150,664 | $131.0K |
| Citigroup Inc | 70,940 | $62.0K |
| Powell Investment Advisors, LLC | 70,000 | $61.0K |
| Susquehanna International Group, LLP | 15,393 | $13.0K |
| Cutler Group LP | 100 | $0 |